Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.10, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

FILSPARI drives IgAN growth, but FSGS approval could unlock a $2 billion market amid rising competition. Read here for more.

Fintel reports that on January 28, 2026, Barclays upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 6.18% Upside As of ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Both platforms are backed by over 50 peer-reviewed publications representing decades of development. The addressable markets span multiple areas: Alzheimer's disease ($32.8 billion by 2033), ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Brian Abrahams of RBC Capital initiated an “Outperform” rating for Vertex Pharmaceuticals Incorporated (VRTX), paving the way for potential upside for investors. With a current price of $461.14 and a ...

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...